Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

Daniel J L Coleman^*
, Peter Keane
, Paulynn S Chin
, Luke Ames
, Sophie Kellaway
, Helen Blair
, Naeem Khan
, James Griffin
, Elizabeth Holmes
, Alexander Maytum
, Sandeep Potluri
, Lara Strate
, Kinga Koscielniak
, Manoj Raghavan
, John Bushweller
, Olaf Heidenreich
, Terry Rabbitts
, Peter N Cockerill
, Constanze Bonifer^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

120 Downloads (Pure)

3 results

Finished
Understanding the rewiring of growth signalling in FLT3-ITD and RAS mutant leukaemias after treatment with FLT3 and RAS inhibitors
Coleman, D. (Principal Investigator)
The Royal Society
1/12/22 → 29/02/24
Project: Research Councils
Pharmaceutical targeting of RAS in Acute Myeloid Leukaemia with RAS mutations or FLT3-ITD
Coleman, D. (Principal Investigator)
LEUKAEMIA UK
1/01/22 → 29/02/24
Project: Research
Finding therapeutic targets in FLT3-ITD AML using a systems biology approach
Cockerill, P. (Co-Investigator) & Bonifer, C. (Principal Investigator)
Medical Research Council
1/09/19 → 31/12/23
Project: Research Councils